# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Previously disclosed 100% response rate across all 10 patients in Part A for pivotal trial primary endpoint of gain/regain of ≥...
Baird analyst Jack Allen maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Outperform and raises the price target from $...
U.S. stocks were mixed, with the Dow Jones index falling more than 50 points on Thursday.
Needham analyst Gil Blum maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Buy and raises the price target from $8 to $10.
Breakthrough Therapy designation granted based on FDA's review of available clinical evidence of safety and efficacy from a...